Incruse® Ellipta® (umeclidinium inhalation powder)

Incruse Ellipta is a prescription medication used to treat chronic obstructive pulmonary disease (COPD). It is a long-acting treatment that can help people with COPD breathe better. Incruse is used once daily as a maintenance treatment.1

What are the ingredients in Incruse?

Incruse contains umeclidinium powder, which is a long-acting muscarinc agent (LAMA) or anticholingeric medicine.2

How does Incruse work?

Anticholinergic medicines like Incruse work by relaxing the muscles in the airways in the lungs. COPD can cause symptoms such as wheezing, cough, chest tightness, and shortness of breath, which occur when the muscles around the airways tighten. By relaxing the muscles in the airways, Incruse can relieve these symptoms, making it easier for people with COPD to breathe.1,3

What are the possible side effects of Incruse?

Common side effects experienced by patients taking Incruse include upper respiratory infection, stuffy or runny nose, cough, sore throat and joint pain. Any side effect that is bothersome or does not go away should be discussed with a healthcare professional.1

Incruse may cause serious side effects, including sudden breathing problems right after inhalation of the medicine or severe allergic reactions, which may appear as a rash, hives, breathing problems, or swelling of the face, mouth, and/or tongue. People who experience these side effects should stop taking Incruse and immediately call their doctor or get emergency medical attention.1

Incruse may cause new or worsened eye problems, including acute narrow-angle glaucoma, which may appear as eye pain or discomfort, nausea or vomiting, blurred vision, seeing halos or bright colors around lights, or red eyes. Patients experiencing these symptoms should talk to their doctor before their next dose of Incruse. Acute narrow-angle glaucoma can cause permanent vision loss if not treated.1

Incruse may cause urinary retention, or a difficulty in passing urine, painful urination, urinating frequently, or urination in a weak stream or drips. Patients who experience these symptoms while taking Incruse should stop their medication and talk to their doctor.1

Things to know about Incruse

Incruse should not be used to treat sudden symptoms of COPD or in the place of a rescue inhaler.1

Some people should not use Incruse. Because it can worsen glaucoma, people with narrow-angle glaucoma should not use Incruse. Incruse may also worsen urinary retention and should not be used by people who have problems passing urine, such as those with prostatic hyperplasia or a bladder-neck obstruction. People who have heart problems should talk to their doctor before using Incruse.1

It is not known whether Incruse is safe during pregnancy or breastfeeding, so women who are pregnant or breastfeeding should talk to their doctor before taking Incruse.1

People with a severe allergy to milk proteins should not use Incruse. Anyone with an allergy to umeclidinium or any of the ingredients in Incruse should not use it.1

Before starting treatment with Incruse, patients should discuss with their doctor all their medical conditions and all the medications (over-the-counter and prescription), vitamins, and supplements they are taking.

Dosing information

Incruse should be used once daily. The powder is inhaled into the lungs through the mouth. Each blister strip of powder contains 62.5 mcg of umeclidinium powder.2

For more information, read the full prescribing information for Incruse Ellipta.

Written by: Emily Downward | Last reviewed: April 2018.
View References